Navigation Links
NeuroSigma Announces Debut of Its Monarch eTNS System in Canada
Date:6/21/2013

and Monarch eTNS are trademarks of NeuroSigma, Inc.

About NeuroSigma, Inc.


NeuroSigma is a Los Angeles-based medical device company established to develop early stage technologies with the potential to transform medical practice and patients' lives.  Currently, NeuroSigma is focused on neuromodulation therapies and has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including TNS therapies for epilepsy, depression, post-traumatic stress disorder (PTSD) and attention-deficit hyperactivity disorder (ADHD). Please visit www.neurosigma.com for more corporate information and www.monarch-etns.com for more information on the Monarch eTNS System.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements, including but not limited to, research and development outcomes, efficacy, adverse reactions, market and product potential, product availability and other statements regarding our eTNS™ and sTNS™ systems.  These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include, among other things, general industry and medical device market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new medical device products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws a
'/>"/>

SOURCE NeuroSigma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression
2. NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder
3. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
4. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
5. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
6. NeuroSigma Receives CE Certification
7. NeuroSigma Receives Global Quality Control Certification
8. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
9. JDRF Announces Two Partnerships to Develop Stable, Pumpable Glucagon to Support Advanced Generation Artificial Pancreas Systems
10. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
11. Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 1, 2015  For many businesses and industries just ... the case, having the right management software can be ... better than software solutions company TraxStar Technologies , ... the company announced the release of the newest version ... "QATrax ...
(Date:4/1/2015)... , April 1, 2015  The U.S. Food ... Sense4Baby™ wireless maternal/fetal monitoring system ... by pregnant patients to self-administer non-stress tests (NST). ... the FDA for use accompanied by medical professionals. ... European Commission in 2013 for self-administration, including the ...
(Date:4/1/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... medical paper has been published describing the positive ... with severe dry eye.  The results met key ... stated that statistically significant differences in both signs ... at various time points throughout the study.  Of ...
Breaking Medicine Technology:TraxStar Technologies Announces Latest QATrax Test Lab Management Software Now Available 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 2AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 3AirStrip Sense4Baby System Receives FDA Clearance for Patient Self-Administration 4RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 2RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea 3
... Md., Dec. 19, 2011 Medical imaging has revolutionized healthcare ... injury and disease. Modern equipment and protocols ensure that ... possible amounts of radiation, while still providing accurate results ... imaging and any medical procedure must be balanced with ...
... CAMBRIDGE, Mass., Dec. 19, 2011 At universities, ... ethics review boards tasked with overseeing the protection ... to improve the quality of reviews and research ... tremendous obligation from federal regulation and face intense pressure from ...
Cached Medicine Technology:AAPM Cautions that Patients Should Not Forgo Essential Medical Imaging 2IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 2IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 3IRBNet Announces 4th Annual IRBNet Ethics in Human Research Protection Award 4
(Date:4/1/2015)... The panel session will look at ... to build a program that can grow in a ... further down the line. This topic has taken on ... that OBD-II port dongles aren’t as secure as the ... was reported that Progressive’s Snapshot dongles contained very significant ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Taking an ... National League for Nursing Commission for Nursing Education ... has approved the first NLN CNEA Board of Commissioners. ... FAAN, ANEF, the 15-member board will provide leadership and ... overseeing all accreditation decisions for nursing programs that seek ...
(Date:4/1/2015)... Eagan, Minn. (PRWEB) April 01, 2015 ... Shield of Minnesota and its family of companies (Blue ... Cross closed out the year with net income of ... slight operational losses. The organization reported a net operating ... billion, for a negative operating margin of one-tenth of ...
(Date:4/1/2015)... April 01, 2015 GrassrootsHealth, an ... two continuing medical education (CME) courses about ... practitioners become more confident in measuring, prescribing, and ... completion of these CME courses, practitioners can apply ... CME courses available are “Vitamin D, Sunshine, Optimal ...
(Date:4/1/2015)... April 01, 2015 Aging2.0 , ... today announces the launch of the Aging2.0 Alliance ... care stakeholders and technology companies. The announcement was made ... Capital and Business Strategies Forum in San Diego, ... new Alliance program is now open for additional members. ...
Breaking Medicine News(10 mins):Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 2Health News:TU-Automotive: Office of The Privacy Commissioner of Canada To Set Out Privacy Considerations Surrounding UBI Products 3Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:GrassrootsHealth Launches CME Courses about Vitamin D 2Health News:GrassrootsHealth Launches CME Courses about Vitamin D 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4
... with mild form of the digestive disorder have slightly higher ... -- People with milder symptoms of celiac disease face a ... study finds. , Cancer and heart disease were the main ... was higher in people who had had small-intestinal biopsies in ...
... researchers say , TUESDAY, Sept. 15 (HealthDay News) -- ... much less likely to survive than white patients, a new ... from the hospital in which black patients receive care, although ... , "We know that survival after having a cardiac arrest ...
... , , , ... Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN ... and Drug Administration (FDA) has approved the company,s supplemental biologics license application ... , , The U.S. licensed Influenza A (H1N1) ...
... , SAN FRANCISCO, Sept. 15 ... Institute for Quantitative Biomedical Research (QB3) at the University ... Discovery, Inc. (CDD) are pleased to announce the prestigious ... Annual Collaborative Drug Discovery - UCSF Community Meeting for ...
... Cowen Group, Inc. (Nasdaq: COWN ) announced today ... in the Investment Banking Group to lead the Firm,s medical technology ... report to Peter Reikes, Head of Cowen,s Health Care Investment Banking ... years of health care investment banking experience and joins Cowen most ...
... INDIANAPOLIS Indiana University School of Medicine scientists ... funded by the federal economic stimulus legislation, funding ... employment on the medical center campus. More ... Reinvestment Act awards ranging from a $1.4 million ...
Cached Medicine News:Health News:Blacks Fare Worse After Cardiac Arrest 2Health News:Blacks Fare Worse After Cardiac Arrest 3Health News:U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine 2Health News:U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine 3Health News:U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine 4Health News:U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine 5Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 2Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 3Health News:3rd Annual Collaborative Drug Discovery - UCSF Community Meeting for Catalyzing Humanitarian and Commercial Research to be Held October 1st 4Health News:Cowen Announces Hiring of Don Munoz to Lead Medical Technology Practice; 5th Senior-Level Addition to Cowen's Health Care Franchise in 2009 2Health News:Indiana U medical researchers boost research and jobs with stimulus legislation grants 2Health News:Indiana U medical researchers boost research and jobs with stimulus legislation grants 3Health News:Indiana U medical researchers boost research and jobs with stimulus legislation grants 4
Enzyme immunoassay for the quantitative determination of Gliadin-IgA antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
... immunosorbent assay method for the semi-quantitative determination ... human serum. The results of the anti-Gliadin ... aid in the diagnosis of diseases associated ... Coeliac Disease. Levels of these autoantibodies are ...
... as a high throughput primary or ... analyzer offers performance and reliability equal ... automated instruments. The advanced technology of ... test strips delivers reproducible and accurate ...
... originally developed for the World Health Organization ... It has been widely used in clinical ... family planning methods. Urine samples are diluted ... by EIA (enzyme labelled immunoassay with magnetic ...
Medicine Products: